Industry update
China issues a new foreign-investment action plan touching biotech pilots, wholly foreign-owned hospitals and commercial insurance
A State Council-approved action plan published on July 30 says authorities will study wider biotech and wholly foreign-owned hospital pilots, support broader commercial-insurance coverage for innovative drugs and devices, and continue opening-up measures in pharmaceuticals and health.
China's July 30 action plan on stabilizing and optimizing foreign investment says the country will support Beijing in advancing services-sector opening and promote trial opening measures in pharmaceuticals and health. The text also says implementation rules for segmented drug production should be accelerated to facilitate cross-border production by overseas marketing authorization holders.
Most relevant for international patients and medical-travel observers, the plan says authorities will promptly study and submit for approval a proposal to further expand pilot regions for opening up in biotechnology and wholly foreign-owned hospitals. It also says insurance companies will be supported in including more innovative drugs and medical devices in commercial insurance coverage.
For PatientChina readers, this is a policy and market-access signal rather than an immediate change in appointment availability, hospital acceptance criteria or treatment pathways. Patients should still confirm whether a specific licensed institution accepts international cases, what services are actually open, how payment works and whether any insurance arrangement applies to their situation.